Thu.Mar 07, 2024

article thumbnail

Girls are starting puberty earlier than ever. For some, that comes with major mental health risks

STAT

Zaria was just 9 years old when a nurse practitioner delivered news that rocked her world: The young girl was already showing signs of puberty development, and she was on track to get her period within the next year. Surprised by this timeline, Zaria’s mother, Chanell, worked with a pediatrician to plan healthier meals, hoping that managing her daughter’s weight gain could give her a couple more precious years with her childhood unchanged.

363
363
article thumbnail

J&J’s growing rare disease focus brings a potential multi-use treatment to the table

PharmaVoice

The head of J&J’s autoantibody programs believes nipocalimab is unique among potential rare disease drugs because it can harness a common thread among them.

187
187
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

RSV monoclonal Beyfortus was 90% effective at preventing hospitalizations in children this winter: CDC

STAT

A new monoclonal antibody product to protect against respiratory syncytial virus was 90% effective at preventing little children from being hospitalized with RSV, according to new data from the first season it was in use. The data , published Thursday in Morbidity and Mortality Weekly Report, a Centers for Disease Control and Prevention publication, looked at how well Beyfortus worked in the children whose parents managed to secure a scarce dose of the drug.

Hospitals 359
article thumbnail

FDA Clears First Over-the-Counter Continuous Glucose Monitor

LifeProNow

March 05, 2024: “The U.S. Food and Drug Administration cleared for marketing the first over-the-counter (OTC) continuous glucose monitor (CGM). The Dexcom Stelo Glucose Biosensor System is an integrated CGM (iCGM) intended for anyone 18 years and older who does not use insulin, such as individuals with diabetes treating their condition with oral medications, or those without diabetes who want to better understand how diet and exercise may impact blood sugar levels.

Diabetes 130
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

STAT+: Nursing home owners can hide nearly two-thirds of their profits, new study shows

STAT

A new study shows that some nursing homes are shunting the majority of their profits off of their own books and into less-visible corners of their owners’ pockets. The practice makes the nursing homes look poorer than they really are, the study’s authors wrote, which seems to bolster the industry’s arguments to Congress that it can’t meet certain proposed quality standards or handle potential Medicare payment cuts.

article thumbnail

LACTOSE-Free Medicines: Which Drugs Contain LACTOSE?

Drug Patent Watch

LACTOSE-Free Medicines, 2024 is part of DrugPatentWatch’s deep library of business intelligence on biopharmaceutical drugs. Buy Lactose-Free Medicines from Amazon This guide is designed to provide information for healthcare providers to… The post LACTOSE-Free Medicines: Which Drugs Contain LACTOSE? appeared first on DrugPatentWatch - Make Better Decisions.

111
111

More Trending

article thumbnail

Gilead and MSD say weekly oral therapy controls HIV

pharmaphorum

Gilead and MSD showcase once-weekly oral HIV regimen at CROI congress, as ViiV presents new data on injectable Cabenuva in patients with low adherence to daily oral therapy

109
109
article thumbnail

In his State of the Union, Biden takes clear aim at ‘Big Pharma’

STAT

WASHINGTON — Often, a president’s State of the Union address is a staid affair, with platitudes and calls for bipartisanship and unity. But President Biden blasted the pharmaceutical industry with its unflattering moniker, “Big Pharma,” not once, but three times Thursday night, only the second time ever that sobriquet has been used in such a setting, after Biden’s address last year.

article thumbnail

GSK scores again with Blenrep in multiple myeloma

pharmaphorum

GSK continues to build the case for its multiple myeloma therapy Blenrep, which was pulled from the US market last year, with another positive phase 3 trial. The BCMA-targeted antibody-drug conjugate (ADC), given in a regimen with pomalidomide plus dexamethasone (PomDex), was shown to be more effective at preventing disease progression or death than Johnson & Johnson’s $10 billion-a-year anti-CD38 antibody Darzalex (daratumumab) with PomDex in the head-to-head DREAMM-8 trial.

108
108
article thumbnail

STAT+: Boehringer Ingelheim to cap asthma inhaler out-of-pocket costs at $35

STAT

Facing criticism over its pricing, Boehringer Ingelheim plans to cap out-of-pocket costs at $35 a month for its entire line of inhalers that are used to combat asthma and chronic obstructive pulmonary disease. The program, which begins on June 1, is directed at Americans with commercial health insurance, but also at those who lack insurance and, therefore, must pay cash for their inhalers.

article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

NodThera says inflammation drug has positive effect in Parkinson’s

BioPharma Dive

The results from the privately held biotech add to early evidence supporting the potential of an increasingly popular drug target known as NLRP3 inflammasomes.

112
112
article thumbnail

STAT+: Novo Nordisk’s obesity pill bests Wegovy in early trial

STAT

A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data. In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting.

Diabetes 303
article thumbnail

Boundless Bio, a Bayer-backed cancer biotech, seeks an IPO

BioPharma Dive

The startup, which has raised nearly $254 million privately, is in early testing with drugs designed to target particularly tough-to-treat tumors.

117
117
article thumbnail

STAT+: Former medical device CEO who sold dummy, plastic parts convicted of fraud

STAT

A New York jury on Wednesday convicted the former CEO of Stimwave, a company that sold devices with dummy pieces of plastic, on two counts of health care fraud. The maximum jail sentence for each count is 20 years. Laura Perryman led Stimwave, which sold nerve stimulation devices to combat pain, from 2010 to 2019. Under her leadership, Stimwave distorted the design of the device to better fit insurance codes, resulting in unnecessary plastic components that allowed the company to sell its produc

290
290
article thumbnail

Cellares Innovates With Automated Cell and Gene Therapy Platform

PharmaTech

Cellares CEO Fabian Gerlinghaus shares how an automated, closed-production platform with a small footprint can dramatically impact cost savings and scalability for cell and gene therapies.

105
105
article thumbnail

STAT+: A deep dive into Applied Therapeutics’ data, and questions on Cassava’s erased data

STAT

Have you heard the news? I’m launching a weekly email newsletter starting on March 28. It’s called Adam’s Biotech Scorecard and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech.

252
252
article thumbnail

Navigating the Current Funding Slowdown While Securing Capital

Pharmaceutical Commerce

In this Pharmaceutical Commerce video interview, Emma Banks, CEO of ramarketing, discusses the biggest roadblocks to the widespread adoption of novel modalities, and how new biotech companies can navigate the current funding slowdown while securing the capital crucial for their success.

105
105
article thumbnail

Banning WuXi is more complicated than it might sound

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Hello, everyone. Damian here with a curious case before the FDA, a State of the Union preview, and the latest IPO to test biotech’s recent resurgence.

article thumbnail

New patent expiration for Takeda Pharms drug ULORIC

Drug Patent Watch

Annual Drug Patent Expirations for ULORIC Uloric is a drug marketed by Takeda Pharms Usa and is included in one NDA. It is available from one supplier. There are three… The post New patent expiration for Takeda Pharms drug ULORIC appeared first on DrugPatentWatch - Make Better Decisions.

105
105
article thumbnail

Listen: VC turmoil, GLP-1 competition, & the war on recovery

STAT

Why are addiction treatments so hard to get? Can small companies compete in obesity? And since when is “Series E” a thing in biotech? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. For the entirety of the opioid overdose epidemic, the U.S. has had readily available tools that are proven to save lives.

189
189
article thumbnail

Novo’s latest obesity pill spurs major weight loss in small trial

BioPharma Dive

Early results from a Phase 1 study suggest the drug, amycretin, could be as potent as injectable medicines already sold by Novo and rival Eli Lilly.

115
115
article thumbnail

How natural language processing can make a difference in pharma

pharmaphorum

On today’s podcast, host Jonah Comstock welcomes Jane Reed, director of life sciences at IQVIA NLP, the new name for recent IQVIA acquisition Linguamatics. Reed talks through some of these different technologies and use cases and describes how natural language processing has exciting potential in translating real-world conversations on social media into pharmaceutical adverse event reports.

101
101
article thumbnail

Vizient: Lack of Information Across Supply Chain Exacerbating Oncology Drug Shortage

vizient

A Vizient white paper demonstrates how the lack of information about medication access across the supply chain is exacerbating the shortage of seven oncology drugs used to treat a multitude of cancers.

98
article thumbnail

UK manufacturing and R&D to benefit from new £360m investment

European Pharmaceutical Review

On 4 March, ahead of the Spring Budget , the UK Chancellor of the Exchequer, Jeremy Hunt, announced a significant investment package for the UK life sciences and manufacturing sectors. A total of £360 million is set to boost UK manufacturing and R&D. Joint government and industry investment of £92 million will help to expand facilities to manufacture life-saving medicines and diagnostics products.

article thumbnail

Sg2 Forecasts Continued Hospital Capacity Challenges as Patient Acuity Rises Over the Next Decade

vizient

Sg2, a Vizient company, released its 2023 Impact of Change Forecast, projecting hospital capacity challenges will continue into the next decade, driven by higher patient acuity and staffing shortages.

article thumbnail

Transition times in the pharma universe 

Express Pharma

The February 16 announcement of Novartis’ strategic review of its India subsidiary, including an assessment of the shareholding of Novartis AG in Novartis India, is the latest sign of MNC pharma’s recalibration of strategic plans for one of the largest pharma markets. Novartis India currently employs nearly 8100 people and is wholly separate from Novartis Healthcare, which includes the Novartis Corporate Center in Hyderabad, the commercial arm of Novartis in India, and R&D teams

article thumbnail

Vizient Hosts Congressional Briefing on Pressures Facing Hospitals

vizient

Yesterday on Capitol Hill, Vizient, Inc. hosted a policy briefing titled, “Provider Pressures Persist: Hospitals' Struggles Against Financial, Workforce and Supply Chain Strains” at the Rayburn House Office Building in Washington, D.C.

article thumbnail

NHS to ensure people eligible for very high-risk breast screening are referred

Pharma Times

Secondary breast cancer is an important risk factor after receiving radiotherapy for Hodgkin lymphoma

117
117
article thumbnail

Vizient Grants Public Access to the Vizient Vulnerability Index™ for Healthcare Providers to Assess Health Equity in their Communities

vizient

The access comes at no cost and provides a unique level of visibility for healthcare organizations to assess social determinants of health that impact health equity in the communities they serve. It is now available to anyone.

98
article thumbnail

US researchers develop algorithm test to identify aggressive ovarian cancers

Pharma Times

Ovarian high-grade serous carcinoma is the most common form of aggressive ovarian cancer

121
121
article thumbnail

Entering into a Medical IT Contract? Here are 7 Factors to Consider.

vizient

From looking at scope of work to dispute resolution clauses, there are several nuanced approaches hospitals can use to achieve success in contracting for information technology services and equipment.

article thumbnail

New ‘vape tax’ to discourage non-smokers from vaping

The Pharmacist

A new tax on vaping products will be introduced from October 2026, chancellor Jeremy Hunt announced in yesterday’s Spring Budget. Health and Social Care Committee (HSCC) chair and Conservative MP for Winchester Steve Brine called for the tax to be implemented even sooner than planned, welcoming it as a move to discourage vaping among children. […] The post New ‘vape tax’ to discourage non-smokers from vaping appeared first on The Pharmacist.

87
article thumbnail

Leading Health System Executive to Evolve High Reliability Solution, Advance Innovative Framework

vizient

Healthcare organizations continue to be tested in their ability to provide safe, efficient care, and managing these multifaceted issues demands a fresh perspective and innovative solutions. That’s where Katerie Chapman, Vizient senior principal, can help.

97
article thumbnail

Employing MALDI-TOF MS for microbial identification in sterile drug manufacturing

European Pharmaceutical Review

A paper published in Frontiers in Microbiology has described an innovative strategy for microbial identification and contamination investigation during sterile manufacturing of drugs. The approach utilised matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) for microbial identification. Over a period of three months, two hundred ninety-two samples were collected covering multiple critical components of raw materials, personnel, environment, and production

88
article thumbnail

Vizient’s New Pharmacy Site of Care Database Helps Providers Formulate Alternate Site of Care Strategy

vizient

With the increasing shift of treatment from inpatient to outpatient settings, come questions about which medications can safely be used at alternate sites of care facilities. The new Vizient Pharmacy Site of Care Database can help answer those questions.